These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 7533699)

  • 21. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.
    Barradell LB; McTavish D
    Drugs; 1993 Apr; 45(4):570-88. PubMed ID: 7684676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group.
    Carel JC; Lahlou N; Guazzarotti L; Joubert-Collin M; Roger M; Colle M; Chaussain JL
    Eur J Endocrinol; 1995 Jun; 132(6):699-704. PubMed ID: 7788009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation study of leuprorelin acetate to improve clinical performance.
    Toguchi H
    Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progestagens and anti-progestagens for pain associated with endometriosis.
    Brown J; Kives S; Akhtar M
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD002122. PubMed ID: 22419284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty.
    Johnson SR; Nolan RC; Grant MT; Price GJ; Siafarikas A; Bint L; Choong CS
    J Paediatr Child Health; 2012 Mar; 48(3):E136-9. PubMed ID: 21564386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leuprolide acetate: a drug of diverse clinical applications.
    Wilson AC; Meethal SV; Bowen RL; Atwood CS
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1851-63. PubMed ID: 17970643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advanced endometriosis treatment with leuprolide acetate].
    Valdés P; Sierralta P
    Rev Chil Obstet Ginecol; 1993; 58(5):405-10. PubMed ID: 7991863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of a GnRH analogue (leuprorelin) in the therapy of endometriosis].
    Grio R; Geranio R; Porpiglia M; Leidi L; Piacentino R
    Minerva Ginecol; 1997 Sep; 49(9):417-9. PubMed ID: 9446077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical applications of gonadotrophin-releasing hormone and its analogues.
    Bartfai G
    Hum Reprod; 1988 Jan; 3(1):51-7. PubMed ID: 3280595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
    Regidor PA; Schindler AE; Bühler K; Gerhard I; Kimmig R; Meinen K; Hoffmann G; Lübben G; Kienle E
    Zentralbl Gynakol; 1996; 118(5):283-90. PubMed ID: 8701625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial.
    Crosignani PG; Gastaldi A; Lombardi PL; Montemagno U; Vignali M; Serra GB; Stella C
    Clin Ther; 1992; 14 Suppl A():29-36. PubMed ID: 1535020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gonadotropin-releasing hormone analogs].
    Krysiak R; Okopień B; Herman ZS
    Pol Merkur Lekarski; 2005 May; 18(107):585-9. PubMed ID: 16161962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Once-a-month injectable microcapsules of leuprorelin acetate].
    Toguchi H; Ogawa Y; Okada H; Yamamoto M
    Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1990 Apr; 39(4):523-51. PubMed ID: 2140979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.
    Verspyck E; Marpeau L; Lucas C
    Eur J Obstet Gynecol Reprod Biol; 2000 Mar; 89(1):7-13. PubMed ID: 10733017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial.
    Serra GB; Panetta V; Colosimo M; Romanini C; Lafuenti GB; Garcea N; Votano S; Agatensi L
    Clin Ther; 1992; 14 Suppl A():57-73. PubMed ID: 1606594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
    Brogden RN; Buckley MM; Ward A
    Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
    Fujisaki A; Kondo Y; Goto K; Morita T
    Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.